Nucleotide News and Research

RSS

Enzyme that helps make tuberculosis resistant to a human's natural defense system identified

Researchers at Iowa State University have identified an enzyme that helps make tuberculosis resistant to a human's natural defense system. Researchers have also found a method to possibly neutralize that enzyme, which may someday lead to a cure for tuberculosis.

3 Oct 2009

Parabon Nanolabs receives SBIR grant to design DNA biometric devices

Parabon NanoLabs (PNL), a leading designer and manufacturer of breakthrough, nano-enabled products, announced today its award of a Department of Homeland Security (DHS) Small Business Innovative Research (SBIR) grant.

1 Oct 2009

BREVAGen test offers precise breast cancer risk assessment

Perlegen Sciences, which develops genetic tests that correlate genetic variation to disease risk and drug response, announced today that its BREVAGen™ breast cancer risk stratification test is now clinically available in select U.S. markets. Perlegen plans to add sales areas to make the test available nationwide over the next few months.

24 Sep 2009

Agilent Technologies and Applied Biosystems to co-market SureSelect system

Agilent Technologies Inc. (NYSE:A) and Applied Biosystems, part of Life Technologies Corp. (NASDAQ:LIFE), today introduced the Agilent SureSelect Target Enrichment System, which is optimized for the SOLiD™ System, a next-generation advanced genomic analysis sequencing platform.

23 Sep 2009

Researchers investigate individual's ability to get rid of Hepatitis C

More than seventy percent of people who contract Hepatitis C will live with the virus that causes it for the rest of their lives and some will develop serious liver disease including cancer. However, 30 to 40 percent of those infected somehow defeat the infection and get rid of the virus with no treatment. In this week's Advanced Online Publication at Nature, Johns Hopkins researchers working as part of an international team report the discovery of the strongest genetic alteration associated with the ability to get rid of the infection.

17 Sep 2009

EPO issues grant for a patent in Kreutzer-Limmer III patent series

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the European Patent Office (EPO) has issued a notification of intent to grant for a patent in the Kreutzer-Limmer III patent series (EP Application No 02702247.4). This patent series stems from the pioneering RNAi research performed by scientists at Ribopharma AG, which was acquired by Alnylam in 2003.

10 Sep 2009

Small molecule blocks aberrant pathway associated with myotonic dystrophy

Researchers at the University of Illinois have designed a small molecule that blocks an aberrant pathway associated with myotonic dystrophy type 1, the most common form of muscular dystrophy.

8 Sep 2009

IRS1 gene could lead to better treatment of type 2 diabetes

A breakthrough by an international team of researchers in Canada, France, the UK and Denmark has uncovered a new gene that could lead to better treatment of type 2 diabetes, as well as a better understanding of how this widespread disease develops.

7 Sep 2009

Scientists identify new genetic variations that are associated with type 2 diabetes

Scientists have identified a genetic variation in people with type 2 diabetes that affects how the body's muscle cells respond to the hormone insulin, in a new study published today in Nature Genetics.

7 Sep 2009

Arrayit receives patent certification from China

Arrayit Corporation (OTCBB: ARYC), a proprietary life sciences technology leader, announces that on August 31st, 2009 the company received a patent certificate from the most populous country on the planet, the People's Republic of China. The patent covers Dr. Mark Schena's microarray methods of genotyping multiple patient samples, commonly referred to as Arrayit's "Variation Identification Platform™" (VIP) technology.

2 Sep 2009

HLA-Cw*0602 gene variation detected as a high risk for psoriasis

A specific genetic region that has been increasingly identified as the strongest genetic link to psoriasis has an even more significant role in the chronic skin disease than has been suspected, University of Utah medical researchers show in a new study.

27 Aug 2009

Relationship between the CD14 variation and the formation of portal lymphoid aggregates discovered

It is still unknown why the natural history of chronic disease caused by hepatitis C virus (HCV), which currently infects 3% of the world's population, varies from mild in some patients to rapidly progressing in others. Age, sex, alcohol consumption and liver sensitivity to gut-derived bacterial endotoxins, were the early factors defined to enhance the risk of fibrosis progression.

27 Aug 2009

University of Maryland researchers perform a genome-wide association study of ADP-stimulated platelet aggregation

Patients with a certain genetic variation who received the antiplatelet drug clopidogrel had a decreased platelet response to treatment and among those who had percutaneous coronary intervention (procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries) had an increased risk of having a cardiovascular event in the following year than patients who did not have this variant, according to a study in the August 26 issue of JAMA.

25 Aug 2009

Santaris Pharma to discover and develop new RNA-based medicines for treating rare genetic disorders

Santaris Pharma A/S, a privately-held biopharmaceutical company focused on developing RNA-based drugs targeted to disease-related mRNAs and microRNAs, today announced a multi-year worldwide strategic alliance with Shire plc to discover and develop new RNA-based medicines to treat rare genetic disorders.

24 Aug 2009

Discovery of inherited gene variants that account for 37 percent of childhood acute lymphoblastic leukemia

Scientists at St. Jude Children’s Research Hospital have identified inherited variations in two genes that account for 37 percent of childhood acute lymphoblastic leukemia (ALL), including a gene that may help predict drug response.

16 Aug 2009

New study suggests possible genetic link between environmental toxins and myeloma

The International Myeloma Foundation (IMF) today said newly published data may provide a possible genetic link between environmental toxins and bone disease in multiple myeloma. Myeloma, also called multiple myeloma, is a cancer of cells in the bone marrow that affect production of blood cells and can damage bone.

14 Aug 2009

Discovery of possible genetic link between environmental toxins and bone disease in multiple myeloma

The International Myeloma Foundation (IMF) - supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians - today said newly published data may provide a possible genetic link between environmental toxins and bone disease in multiple myeloma.

13 Aug 2009

Inhibitex reports Q2 2009 financials

Inhibitex, Inc. (Nasdaq: INHX), today announced its financial results for the second quarter ended June 30, 2009. The Company held cash, cash equivalents and short-term investments of $24.5 million at June 30, 2009, as compared to $33.1 million at December 31, 2008.

12 Aug 2009

Genetic link to ovarian cancer found

Scientists have located a region of DNA which - when altered - can increase the risk of ovarian cancer according to research published in Nature Genetics today.

3 Aug 2009

Discovery of gene linked to follicular lymphoma

California and Arizona researchers have identified a gene variant that carries nearly twice the risk of developing an increasingly common type of blood cancer, according to a study published online today by the science journal Nature Genetics.

20 Jul 2009